Top news of the week: 24.11.2020.
Initial public offering, Industry, Federal government of the United States, Thrombocytopenia, Drug, Graft-versus-host disease
Startups
RT @adamfeuerstein: EXCLUSIVE: Raging at the pandemic, VC @rtnarch raises $800M for a company that aims to transform biotech manufacturing https://t.co/aq15ExLgkR via @matthewherper @damiangarde
OpenRaging at the pandemic, a VC raises $800M for a company that aims to transform biotech manufacturing
The board of the new company, Resilience, includes a who’s who of former industry and government officials.
RT @DShaywitz: Love this @nytimes story about the heroic efforts to deliver a SARS-CoV-2 vaccine - science FTW! Biopharma FTW! https://t.co/VjVvO1QrBk @zakkohane @ScottGottliebMD @LifeSciVC @NoubarAfeyan @ldtimmerman @adamjshay https://t.co/tSXG9wBE7h
OpenPolitics, Science and the Remarkable Race for a Coronavirus Vaccine
The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.
Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast https://t.co/Om8dNqZQsk https://t.co/eZwuY1Gipo
OpenNovartis licenses phase 3 COVID-19 cell therapy from Mesoblast
Novartis has secured a global license to Mesoblast’s cell therapy remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and the support of a partner that ...
RT @Forbes: Here’s what you need to know about AstraZeneca’s Covid-19 vaccine: https://t.co/APhPp4nWHQ https://t.co/hsNcZgHiY1
OpenHere’s What You Need To Know About AstraZeneca’s Covid-19 Vaccine
AstraZeneca, with partner Oxford University, released preliminary data for its phase 3 Covid-19 Monday showing that the vaccine may be up to 90% effective.
RT @peterjhebert: The once obscure, derided financial product that just might transform deep tech venture capital https://t.co/3EBKr2YyZM
OpenThe once obscure, derided financial product that just might transform deep tech venture capital
By Peter Hébert
Biotech: The Featherweight Champion Of The Markets.
Its a sector that punches way higher than its weight class: while a small sector in the overall stock market, biopharma has been growing in it's share of funding flows relative to other sectors.
https://t.co/XQrx38chQg
OpenBiotech: The Featherweight Champion Of The Markets
Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine. For those of us in biopharma, it feels like it’s a ...
Pfizer strikes a deal with newly formed China #biotech https://t.co/2VtomIi7cC by Kristin Jensen $PFE
OpenPfizer strikes a deal with newly formed China biotech
The deal, which has Pfizer paying as much as $70 million, is the latest in a series of moves by big pharma companies to forge a stronger position in the world's second-largest drug market.
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M https://t.co/iGa3frOuMh https://t.co/1yvfTH3MP8
OpenBelgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Big Pharma friend argenx has snapped up an FDA priority review voucher from Bayer for $98 million.